Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Legend Biotech Corp ADR (LEGN)

Legend Biotech Corp ADR (LEGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,298,564
  • Shares Outstanding, K 184,690
  • Annual Sales, $ 627,240 K
  • Annual Income, $ -177,030 K
  • EBIT $ -278 M
  • EBITDA $ -255 M
  • 60-Month Beta 0.07
  • Price/Sales 3.62
  • Price/Cash Flow N/A
  • Price/Book 3.37

Options Overview Details

View History
  • Implied Volatility 103.61% (+18.18%)
  • Historical Volatility 55.80%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 103.61% on 03/04/26
  • IV Low 43.54% on 11/14/25
  • Expected Move (DTE 16) 1.96 (11.00%)
  • Put/Call Vol Ratio 10.09
  • Today's Volume 488
  • Volume Avg (30-Day) 562
  • Put/Call OI Ratio 0.48
  • Today's Open Interest 21,453
  • Open Int (30-Day) 25,035
  • Expected Range 15.89 to 19.81

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 17 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.17
  • Number of Estimates 7
  • High Estimate 0.12
  • Low Estimate -0.38
  • Prior Year -0.15
  • Growth Rate Est. (year over year) -13.33%

Price Performance

See More
Period Period Low Period High Performance
1-Month
16.60 +7.53%
on 02/05/26
21.58 -17.28%
on 02/23/26
+1.20 (+7.21%)
since 02/04/26
3-Month
16.24 +9.91%
on 02/04/26
28.97 -38.38%
on 12/05/25
-9.96 (-35.81%)
since 12/04/25
52-Week
16.24 +9.91%
on 02/04/26
45.30 -60.59%
on 07/23/25
-16.13 (-47.47%)
since 03/04/25

Most Recent Stories

More News
Legend Biotech to Host Investor Conference Call on Fourth Quarter and Full Year 2025 Results

SOMERSET, N.J., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET...

LEGN : 17.85 (-0.06%)
Legend Biotech to Present CARVYKTI® Data at 2026 Tandem Meetings Reinforcing Growing Evidence Supporting Earlier Use

Six poster presentations highlight CARVYKTI® efficacy, safety, and real-world outcomes across CARTITUDE trials and analyses, reflecting a maturing and expanding body of evidence SOMERSET, N.J., Jan....

LEGN : 17.85 (-0.06%)
Legend Biotech to Present at the 44th Annual J.P. Morgan Healthcare Conference

SOMERSET, N.J., Dec. 17, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, today announced that Ying Huang, Ph.D., the company’s...

LEGN : 17.85 (-0.06%)
Legend Biotech Highlights New CARVYKTI® Data in Multiple Myeloma and First-in-Human Results from Novel CAR-T Platform in Non-Hodgkin Lymphoma at ASH 2025

Triple-class exposed patients with three prior lines of therapy in CARTITUDE-1 and CARTITUDE-4 achieved a median PFS of 50.4 months after a single infusion of CARVYKTI ® Translational analyses...

LEGN : 17.85 (-0.06%)
Legend Biotech Celebrates Official Opening of New State-of-the-Art Cell Therapy Research and Development Facility in Philadelphia

31,000-square-foot site expands Legend’s U.S. R&D footprint and strengthens its position as a global leader in cell therapy innovation The facility will support CAR-T R&D in potential oncology and...

LEGN : 17.85 (-0.06%)
Legend Biotech Reports Third Quarter 2025 Results and Recent Highlights

CARVYKTI ® (ciltacabtagene autoleucel; cilta-cel) net trade sales of approximately $524 million EC and U.S. FDA label updates for CARVYKTI ® to include overall survival benefit versus standard...

LEGN : 17.85 (-0.06%)
Legend Biotech Announces 10 Presentations at the 67th American Society of Hematology (ASH) Annual Meeting

Two oral and seven poster presentations further support the CARVYKTI ® research in multiple myeloma First-in-Human Phase 1 data for allogeneic CAR-T cell therapy for NHL to be featured in oral session...

LEGN : 17.85 (-0.06%)
Legend Biotech to Host Investor Conference Call on Third Quarter 2025 Results

SOMERSET, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET...

LEGN : 17.85 (-0.06%)
Legend Biotech’s CARVYKTI® Receives FDA Approval for Label Update with New Survival Data

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Legend Biotech...

LEGN : 17.85 (-0.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. It engaged in the discovery and development of novel cell therapies for oncology and other indications. The company's lead product consist LCAR-B38M/JNJ-4528, which are in clinical stage. Legend Biotech Corporation is based in...

See More

Key Turning Points

3rd Resistance Point 18.83
2nd Resistance Point 18.52
1st Resistance Point 18.19
Last Price 17.85
1st Support Level 17.55
2nd Support Level 17.24
3rd Support Level 16.91

See More

52-Week High 45.30
Fibonacci 61.8% 34.20
Fibonacci 50% 30.77
Fibonacci 38.2% 27.34
Last Price 17.85
52-Week Low 16.24

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar